A case of late-onset larynx angioedema after ranibizumab intravitreal injection: Ranibizumab-related angioedema.
Aged
Angioedema
/ chemically induced
Angiogenesis Inhibitors
/ administration & dosage
Betamethasone
/ administration & dosage
Female
Glucocorticoids
/ administration & dosage
Humans
Injections, Intramuscular
Intravitreal Injections
Laryngeal Edema
/ chemically induced
Ranibizumab
/ administration & dosage
Time Factors
Treatment Outcome
adverse drug reaction
angioedema
intravitreal injection
ranibizumab
subglottic edema
Journal
International journal of immunopathology and pharmacology
ISSN: 2058-7384
Titre abrégé: Int J Immunopathol Pharmacol
Pays: England
ID NLM: 8911335
Informations de publication
Date de publication:
Historique:
entrez:
22
8
2020
pubmed:
22
8
2020
medline:
8
7
2021
Statut:
ppublish
Résumé
This case report describes an unusual case of late-onset larynx angioedema after ranibizumab intravitreal injection. A 72-year-old female patient presented to our clinic for decreased vision; right eye (RE) fundoscopy and optical coherence tomography (OCT) revealed mild chorioretinal atrophy and choroidal neovascularization with subretinal fluid. A ranibizumab injection was planned in the RE, with standard pretreatment with daily oral administration of betamethasone, cetirizine, and ranitidine because her medical history revealed two adverse drug reactions (ADRs) to contrast media (CM). Despite the premedication, 2 h after injection, the patient referred throat closing sensation and dyspnea that resolved within few hours by betamethasone 4 mg intramuscular injection, without further reoccurrence. In occasion of the second intravitreal injection, video rhinofibrolaryngoscopy revealed subglottic edema that resolved within few hours by betamethasone 4 mg intramuscular injection. This report suggests that, even in cases of intravitreal injection, patients with history of allergy, despite the anti-allergic treatment, should be hospitalized to detect late onset of such a life-threatening complication.
Identifiants
pubmed: 32820959
doi: 10.1177/2058738420929173
pmc: PMC7444152
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Glucocorticoids
0
Betamethasone
9842X06Q6M
Ranibizumab
ZL1R02VT79
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
2058738420929173Références
J Allergy Clin Immunol. 2004 May;113(5):832-6
pubmed: 15131563
Cutan Ocul Toxicol. 2012 Mar;31(1):85-6
pubmed: 22309281
Ann Allergy Asthma Immunol. 2010 Oct;105(4):259-273
pubmed: 20934625
Curr Opin Allergy Clin Immunol. 2010 Oct;10(5):457-62
pubmed: 20706115
Neuroradiol J. 2019 Jun;32(3):227-228
pubmed: 30793659
Physiol Meas. 2018 Jun 01;39(5):058001
pubmed: 29767627
Allergy. 2013 Jun;68(6):702-12
pubmed: 23617635
Ophthalmologe. 2017 Jul;114(7):639-645
pubmed: 27815675
Retin Cases Brief Rep. 2019 Summer;13(3):287-289
pubmed: 28301410